Aldosterone levels and inflammatory stimulation in essential hypertensive patients

Journal of Human Hypertension

Volumn 27, Issue 9, 2013, Pages 535-538

  Tzamou, V ^a   Vyssoulis, G ^a   Karpanou, E ^b   Kyvelou, S M ^a   Gialernios, T ^a   Stefanadis, C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

aldosterone; essential hypertension; inflammation; plasma renin activity

Indexed keywords

ALDOSTERONE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERUM AMYLOID A; SODIUM; TRIACYLGLYCEROL;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORTICOSTEROID METABOLISM; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PHYSICAL EXAMINATION; PLASMA RENIN ACTIVITY; SMOKING; SMOKING HABIT; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALDOSTERONE; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FIBRINOGEN; HOMOCYSTEINE; HUMANS; HYPERTENSION; INFLAMMATION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RENIN; RISK FACTORS;

EID: 84882456843     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.13     Document Type: Article

References (25)

1. Freel EM, Connell JM. Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol 2004; 15: 1993-2001.
2. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41.
3. Ma ckenzie SM, Connell J. Hypertension and the expanding role of aldosterone. Curr Hypertens Rep 2006; 8: 255-261.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
5. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
6. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress inresistance arteries of angiotensin II-infused macrophage colony- stimulatingfactor-deficient mice: evidence for a role in inflammation in angiotensin induced vascular injury. Arterioscler Thromb Vasc Biol 2005; 25: 2106-2113.
7. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 2: 152-158.
8. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 2007; 112: 375-384.
9. Pietri P, Vyssoulis G, Vlachopoulos C, Zervoudaki A, Gialernios T, Aznaouridis K et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 2006; 24: 2231-2238.
10. Blake JG, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763-771.
11. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
12. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999.
13. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 2: 1-40.
14. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S et al. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens 2007; 2510: 2131-2137.
15. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010; 17: 199-20.
16. Kurata M, Okura T, Irita J, Enomoto D, Nagao T, Jotoku M et al. The relationship between osteopontin and adiponectin in patients with essential hypertension. Clin Exp Hypertens 2010; 32: 358-363.
17. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113: 267-278.
18. Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y. Aldosterone and TGF-b1 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 2008; 294: F1287-F1295.
19. Sechi LA, Novello M, Colussi G, Di Fabio A, Chiuch A, Nadalini E et al. Relationship of plasma renin with aprothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 2008; 21: 1347-1353.
20. Calhoun DA. Aldosteronism and hypertension. Clin J Am Soc Nephrol 2006; 1: 1039-1045.
21. Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B. Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26: 381-391.
22. Rodrnguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chávez M, Herrera-Acosta J et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282: F191-F201.
23. Alvarez V, Quiroz Y, Nava M, Pons H, Rodrnguez-Iturbe B. Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002; 283: F1132-F1141.
24. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42: 31-38.
25. Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G et al. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens 1998; 11: 921-928.